Algernon Pharmaceuticals Archives | Page 2 of 2 | Be Korea-savvy
Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus

Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus

VANCOUVER, British Columbia, March 19 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 [...]

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

VANCOUVER, British Columbia, March 13 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that is has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA. This initiates formal communications with the U.S. FDA regarding development [...]

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, March 10 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that BioPub recently hosted an interview by Dr. KSS of the Company’s CEO and CSO. The 35 minute interview provides additional insight into the Company’s recent developments surrounding [...]

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

VANCOUVER, British Columbia, March 9 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to [...]

Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus

Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus

VANCOUVER, British Columbia, March 6 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it will set aside some of its NP-120 (Ifenprodil) drug supply from its planned phase 2 study for idiopathic fibrosis and chronic cough, to [...]

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

VANCOUVER, British Columbia, March 6 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it is exploring the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19, also known as the coronavirus. A recent independent study [...]